Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate. Review uri icon

Overview

abstract

  • Polycythemia vera is a myeloproliferative disease, which, if untreated, leads to thrombohemorrhagic complications and eventually to progressive myelofibrosis, anemia, and splenomegaly. Two newly available drugs, interferon alfa and imatinib mesylate, may alter the course of this disease. Used as single agents, each produces lasting remissions in about 75% of patients with polycythemia vera. Of significance, change in JAK2 expression has been reported after treatment with both agents.

publication date

  • February 1, 2007

Research

keywords

  • Interferon Type I
  • Piperazines
  • Polycythemia Vera
  • Protein Kinase Inhibitors
  • Pyrimidines

Identity

Scopus Document Identifier

  • 34250782027

Digital Object Identifier (DOI)

  • 10.1007/s11899-007-0006-2

PubMed ID

  • 20425387

Additional Document Info

volume

  • 2

issue

  • 1